Published in Endocrinology, research shows that GLP-1 receptor agonists commonly used for diabetes and obesity may also help treat alcohol use disorder. Studies in animals and humans found reduced drinking, cravings, and relapse with drugs like semaglutide, offering hope for future addiction treatments.